BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

Special Reports

All News

FDA Briefs

Oncology Icons

The Targeted Pulse

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Evolving Paradigms in Oncology

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Personalized Medicine

Pivotal Practice Views with the Oncology Brothers

Podcasts

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Events

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Editorial Board

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

Myeloma

Genomic Testing

This roundtable series reviews treatment after progression for patients with advanced melanoma, as discussed by key opinion leaders at virtual live events and interviews.

Later-Line Therapies Used in Unresectable or Metastic Melanoma

Behind the C-144-01 Study of Lifileucel in Melanoma 

Theresa Medina, MD, associate professor of medicine-medical oncology at the University of Colorado Cancer Center, Anschutz Medical Campus, discusses treatment with lifileucel (Amtagvi) in patients with advanced melanoma and the background of the C-144-01 study (NCT02360579).


Lifileucel represents a significant advance as a personalized, one-time tumor-derived autologous T-cell immunotherapy. It is currently approved for the treatment of adult patients with unresectable or metastatic melanoma that has progressed following programmed cell death-1 (PD-1) blocking antibody and, if applicable, a BRAF inhibitor with or without a MEK inhibitor.

“The C-144-01 study was the first global, multicenter study looking at the use of what we call TIL, or tumor-infiltrating lymphocyte therapy, which actually has a really long history, but it was the first opportunity for multiple centers across the world to have access to this unique approach,” explains Medina in an interview with Targeted Oncology

“It was a trial looking at patients who are refractory to standard therapies with immune checkpoint inhibitors and, when applicable, targeted therapies as a kind of additional line of therapy. It was the first study looking at, again, in the global setting, a cellular-based approach option for patients with solid tumors,” she adds.

C-144-01 is a phase 2, registrational, open-label, multicenter, multicohort trial that previously demonstrated compelling efficacy. Patients treated with lifileucel achieved an objective response rate (ORR) of 31.4% as assessed by an independent review committee.

The C-144-01 study enrolled patients with advanced melanoma who had progressed on prior immune checkpoint inhibitors and, where appropriate, targeted therapy. The treatment regimen involved nonmyeloablative lymphodepletion (cyclophosphamide and fludarabine) prior to a single infusion of cryopreserved lifileucel, followed by a short course of interleukin-2. Beyond ORR, key secondary end points of the trial were duration of response, overall survival, and safety.

“It was a modified intention-to-treat analysis with the patients that received lifileucel that were evaluated in that overall survival,” she says.




Theresa Medina, MD, discusses treatment with lifileucel in patients with advanced melanoma and the background of the C-144-01 study.